XML 38 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SIGNIFICANT ACCOUNTING POLICIES (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Aug. 29, 2022
May 13, 2021
USD ($)
Jul. 23, 2018
USD ($)
Oct. 19, 2017
USD ($)
Oct. 31, 2015
Jun. 30, 2024
USD ($)
agreement
$ / shares
shares
Jun. 30, 2023
USD ($)
shares
Mar. 31, 2023
USD ($)
shares
Jun. 30, 2024
USD ($)
agreement
$ / shares
shares
Jun. 30, 2023
USD ($)
shares
Dec. 31, 2023
$ / shares
Feb. 27, 2023
USD ($)
Jul. 02, 2021
USD ($)
$ / shares
Significant Accounting Policies [Line Items]                          
Number of global licensing and supply agreements | agreement           2     2        
Common Stock, Par or Stated Value Per Share | $ / shares           $ 0.001     $ 0.001   $ 0.001    
Stock issuance proceeds                   $ 23,954      
Antidilutive securities excluded from computation of earnings per share, amount | shares           31,744,960 1,896,733   31,791,645 16,158,086      
ATM Shares                          
Significant Accounting Policies [Line Items]                          
Number of shares issued (in shares) | shares               13,980,060          
Common Stock, Par or Stated Value Per Share | $ / shares                         $ 0.001
Sale of stock, maximum offering price           $ 6,400     $ 6,400     $ 20,000 $ 20,000
Stock issuance proceeds               $ 20,000          
2024 Notes                          
Significant Accounting Policies [Line Items]                          
Interest rate (as a percent)           7.50%     7.50%        
Minimum cash balance required           $ 7,500     $ 7,500        
Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil                          
Significant Accounting Policies [Line Items]                          
Collaborative arrangement revenues and expenses sharing percentage         100.00%                
Chiesi Agreements                          
Significant Accounting Policies [Line Items]                          
Amount of milestone payment received             $ 20,000   $ 20,000        
Chiesi US Agreement                          
Significant Accounting Policies [Line Items]                          
Additional amounts payable to cover development costs     $ 20,000                    
Additional amount payable for achievement of regulatory and commercial milestones     $ 760,000                    
Chiesi US Agreement | Minimum                          
Significant Accounting Policies [Line Items]                          
Payment on net sales percentage     15.00%                    
Chiesi US Agreement | Maximum                          
Significant Accounting Policies [Line Items]                          
Payment on net sales percentage     40.00%                    
Chiesi Ex-US Agreement                          
Significant Accounting Policies [Line Items]                          
Additional amounts payable to cover development costs       $ 25,000                  
Agreement amendment payment receivable   $ 10,000                      
Change in amount receivable for achievement of regulatory and commercial milestones   $ 25,000                      
Additional amount payable for achievement of regulatory and commercial milestones       $ 320,000                  
Chiesi Ex-US Agreement | Minimum                          
Significant Accounting Policies [Line Items]                          
Payment on net sales percentage       15.00%                  
Chiesi Ex-US Agreement | Maximum                          
Significant Accounting Policies [Line Items]                          
Payment on net sales percentage       35.00%                  
Chiesi US Agreement and Chiesi Ex-US Agreement                          
Significant Accounting Policies [Line Items]                          
Non-refundable payment receivable     $ 25,000 $ 25,000                  
Fill/Finish Agreement                          
Significant Accounting Policies [Line Items]                          
Extended term of agreement 7 years